Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy.

Felicetto FerraraLaura SantoniChiara RicellaLuca Prosperini

Published in: BMC health services research (2019)

Adopting the Italian social perspective, early escalation to natalizumab is dominant vs. switching among immunomodulators, in RRMS patients who do not respond adequately to conventional immunomodulators.

Keyphrases

multiple sclerosis
white matter
healthcare
mental health
open label
randomized controlled trial
clinical trial
rheumatoid arthritis
disease activity